
March 4 (Reuters) - PepGen Inc PEPG.O:
PEPGEN INC: U.S. FDA PLACES FREEDOM2 TRIAL ON PARTIAL CLINICAL HOLD RELATED TO PRECLINICAL PHARMACOLOGY AND TOXICOLOGY
PEPGEN INC: REITERATES GUIDANCE FOR REPORTING DATA FROM FREEDOM2 5 MG/KG COHORT IN Q1 2026 AND FROM 10 MG/KG COHORT IN 2H 2026
PEPGEN INC - RECEIVES REGULATORY CLEARANCE TO INITIATE FREEDOM2 IN SOUTH KOREA, AUSTRALIA, AND NEW ZEALAND